MedTrace Logo

A Study of Oral EX039 in Subjects with Mild Alzheimer's Disease

NCT05413655 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-02-26

No results posted yet for this study

Summary

This is a phase 2, randomized, double-blind, placebo-controlled study of oral EX039 as add-on to Acetylcholine Esterase Inhibitors in subjects with mild Alzheimer's disease.

Conditions

  • Alzheimer Disease

Interventions

DRUG

EX039

The dosage form of EX039 is the capsule for oral use

DRUG

Placebo

The dosage form of Placebo is the capsule for oral use

Sponsors & Collaborators

  • Formosa Biomedical Technology Corp.

    collaborator UNKNOWN

  • Excelsior

    lead INDUSTRY

Principal Investigators

  • Ching-Kuan Liu, Dr. · Kaohsiung Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-08
Primary Completion
2026-12-31
Completion
2027-02-28

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05413655 on ClinicalTrials.gov